Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest MiMedx Group Inc. Stories

2014-01-13 12:28:02

MARIETTA, Ga., Jan. 13, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced the schedule for its presentation at the 32(nd) Annual J.P. Morgan Healthcare Conference. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday,...

2013-12-12 12:27:38

6 of 8 Medicare Administrative Contractors Now Cover MiMedx EpiFix® Wound Care Allografts MARIETTA, Ga., Dec. 12, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, CGS, has confirmed that the Company's wound care allograft, EpiFix®, has received reimbursement coverage from CGS. The...

2013-12-12 08:31:24

MARIETTA, Ga., Dec. 12, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $6.80 per share for gross proceeds of $34.0 million. The net proceeds from the sale of the shares, after deducting the...

2013-12-09 08:27:27

MARIETTA, Ga., Dec. 9, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today its intention to offer, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 750,000...

2013-12-05 08:29:26

MARIETTA, Ga., Dec. 5, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, provided an update yesterday on its continuing discussions with the Food & Drug Administration (FDA) regarding the regulatory classification of its micronized products. In addition, on November 29(th), MiMedx announced its support of the new...

2013-12-04 16:26:12

COMPANY REITERATES GUIDANCE MARIETTA, Ga., Dec. 4, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, provided an update today on its continuing discussions with the Food & Drug Administration (FDA) regarding the regulatory classification of its micronized products. The Company received a communication from the FDA...

2013-11-29 08:24:28

EPIFIX® CURRENT REIMBURSEMENT STATUS EXTENDED THROUGH 2014 MARIETTA, Ga., Nov. 29, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company applauds the Centers for Medicare and Medicaid Services' (CMS) new methodology for the reimbursement of skin substitutes in the hospital outpatient setting,...

2013-11-26 12:27:16

STUDIES DEMONSTRATE STRONG HEALING RESULTS OF EPIFIX® AND AMNIOFIX® MARIETTA, Ga., Nov. 26, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the summaries of a selection of the seven posters highlighting MiMedx allografts presented at the recent 10(th) Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix,...

2013-11-19 12:30:05

Follow Up Study Accepted For Publication In Wound Medicine MARIETTA, Ga., Nov. 19, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Dehydrated Human Amnion/Chorion Membrane Allografts in Patients with Chronic Diabetic Foot Ulcers: A Long-term Follow-up Study" has been accepted for publication...

2013-10-31 12:26:26

MARIETTA, Ga., Oct. 31, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer,...